Physician profile
Mackenzie Stanley
NPI 1992402291
$2,433.63
in general payments reported to CMS, 2019-2025
11 companies · $678 in 2025
The $678 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $932 · 2024: $824 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $611.28 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $365.77 | 2023-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $346.88 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $203.28 | 2024-2025 | |
| Ucb, INC. | $192.17 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $182.21 | 2023-2025 | Cosentyx |
| Genzyme Corporation | $179.07 | 2025 | |
| Abbvie INC. | $124.99 | 2023 | |
| Incyte Corporation | $116.48 | 2023 | Opzelura |
| Janssen Biotech, INC. | $91.50 | 2024 | Tremfya |
| Amgen INC. | $20.00 | 2023 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Stanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.